An attenuated Shigella mutant lacking the RNA-binding protein Hfq provides cross-protection against Shigella strains of broad serotype
Open Access
- 20 July 2017
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS Neglected Tropical Diseases
- Vol. 11 (7) , e0005728
Abstract
Few live attenuated vaccines protect against multiple serotypes of bacterial pathogen because host serotype-specific immune responses are limited to the serotype present in the vaccine strain. Here, immunization with a mutant of Shigella flexneri 2a protected guinea pigs against subsequent infection by S. dysenteriae type 1 and S. sonnei strains. This deletion mutant lacked the RNA-binding protein Hfq leading to increased expression of the type III secretion system via loss of regulation, resulting in attenuation of cell viability through repression of stress response sigma factors. Such increased antigen production and simultaneous attenuation were expected to elicit protective immunity against Shigella strains of heterologous serotypes. Thus, the vaccine potential of this mutant was tested in two guinea pig models of shigellosis. Animals vaccinated in the left eye showed fewer symptoms upon subsequent challenge via the right eye, and even survived subsequent intestinal challenge. In addition, oral vaccination effectively induced production of immunoglobulins without severe side effects, again protecting all animals against subsequent intestinal challenge with S. dysenteriae type 1 or S. sonnei strains. Antibodies against common virulence proteins and the O-antigen of S. flexneri 2a were detected by immunofluorescence microscopy. Reaction of antibodies with various strains, including enteroinvasive Escherichia coli, suggested that common virulence proteins induced protective immunity against a range of serotypes. Therefore, vaccination is expected to cover not only the most prevalent serotypes of S. sonnei and S. flexneri 2a, but also various Shigella strains, including S. dysenteriae type 1, which produces Shiga toxin. An ideal vaccine should show a broad range of protective efficacy against all serotypes of a particular pathogen. Variations in the structural lipopolysaccharide “O”-antigen mean that it is difficult to induce protection against multiple serotype Shigella strains using a single serotype immunogen. Here, we examined vaccination effects of an attenuated S. flexneri hfq mutant strain overexpressing virulence proteins common to all Shigella serotypes, which was identified from our studies on temperature and osmotic-dependent regulation of the type III secretion system: an essential virulence machinery among Shigella and enteroinvasive Escherichia coli species. The deletion mutant lacked the RNA-binding protein Hfq, which led to increased expression of the type III secretion system via loss of regulation, resulting in attenuation of cell viability through repression of stress response sigma factors. Immunization with the hfq mutant of S. flexneri 2a induced systemic immunity and cross-protective efficacy against two different serotypes of Shigella strain: S. dysenteriae type 1 and. S. sonnei. Detection of anti-Shigella antibodies against various strains with different serotypes suggests that generation of antibodies specific for common virulence proteins affords cross-protection against Shigella strains of multiple serotypes.Keywords
Funding Information
- Ministry of Health, Labor, and Welfare of Japan (Health Labor Sciences Research Grants for Emerging and Re-emerging Infectious Diseases (H23-Shinkou-Shitei-020 and 26361101))
- Japan Agency for Medical Research and Development (Research Program on Emerging and Re-emerging Infectious Diseases (15fk0108027h0902))
- Japan Society for the Promotion of Science (KAKENHI (#17790299))
- Japan Society for the Promotion of Science (KAKENHI (#26440014))
This publication has 43 references indexed in Scilit:
- An update on vaccines against ShigellaTherapeutic Advances in Vaccines, 2013
- Broadly Protective Shigella Vaccine Based on Type III Secretion Apparatus ProteinsInfection and Immunity, 2012
- Development of a new guinea-pig model of shigellosisFEMS Immunology & Medical Microbiology, 2011
- Salmonella enterica Serovar Typhimurium Lacking hfq Gene Confers Protective Immunity against Murine TyphoidPLOS ONE, 2011
- Safety, dose, immunogenicity, and transmissibility of an oral live attenuated Shigella flexneri 2a vaccine candidate (SC602) among healthy adults and school children in Matlab, BangladeshVaccine, 2011
- Involvement of RNA-binding protein Hfq in the osmotic-response regulation of invE gene expression in Shigella sonneiBMC Microbiology, 2009
- Hfq Modulates the σ E -Mediated Envelope Stress Response and the σ 32 -Mediated Cytoplasmic Stress Response in Escherichia coliJournal of Bacteriology, 2007
- A Multicentre Study of Shigella Diarrhoea in Six Asian Countries: Disease Burden, Clinical Manifestations, and MicrobiologyPLOS Medicine, 2006
- A Pediatric Cluster of Shigella dysenteriae Serotype 1 Diarrhea with Hemolytic Uremic Syndrome in 2 Families from FranceClinical Infectious Diseases, 2004
- Virulence phenotype and genetic characteristics of the T32-ISTRATI Shigella flexneri 2a vaccine strainVaccine, 1991